Pancreatic Cancer Research

ResearcherMemorial Sloan Kettering Cancer CenterActive in the last 2 years

David Paul Kelsen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6139-438X; OpenAlex author ID A5069929201, A5112035685. Sources: ClinicalTrials.gov.

Their work

Papers
24 (first author 2, last author 1)
Trials
2 (principal investigator on 1)
Grants
0
Labs led
0
Collaborators
90
Papers, trials and grants by year

1998: 1 trial · 1999: none · 2000: none · 2001: none · 2002: none · 2003: none · 2004: none · 2005: none · 2006: none · 2007: none · 2008: none · 2009: none · 2010: none · 2011: 3 papers · 2012: 3 papers · 2013: 1 paper, 1 trial · 2014: 1 paper · 2015: 1 paper · 2016: 1 paper · 2017: 2 papers · 2018: 2 papers · 2019: none · 2020: 2 papers · 2021: 2 papers · 2022: 2 papers · 2023: none · 2024: 1 paper · 2025: 2 papers · 2026: 1 paper

Papers 24

  1. Pembrolizumab and olaparib in homologous-recombination-deficient metastatic pancreatic cancer: the phase 2 POLAR trial. Co-author DOI 10.1038/s41591-026-04299-5↗
  2. Clinicogenomic landscape of pancreatic adenocarcinoma identifies KRAS mutant dosage as prognostic of overall survival. Co-author DOI 10.1038/s41591-024-03362-3↗
  3. Adjuvant modified FOLFIRINOX for resected pancreatic adenocarcinoma: clinical insights and genomic features from a large contemporary cohort. Co-author DOI 10.1093/jnci/djae269↗
  4. Multi-parametric atlas of the pre-metastatic liver for prediction of metastatic outcome in early-stage pancreatic cancer. Co-author DOI 10.1038/s41591-024-03075-7↗
  5. Circulating tumor and invasive cell expression profiling predicts effective therapy in pancreatic cancer. Co-author DOI 10.1002/cncr.34269↗
  6. BRCA mutational status shapes the stromal microenvironment of pancreatic cancer linking clusterin expression in cancer associated fibroblasts with HSF1 signali… Co-author DOI 10.1038/s41467-022-34081-3↗
  7. Artificial Intelligence and Early Detection of Pancreatic Cancer: 2020 Summative Review. Co-author DOI 10.1097/mpa.0000000000001762↗
  8. Conformation-Specific Inhibitory Anti-MMP-7 Monoclonal Antibody Sensitizes Pancreatic Ductal Adenocarcinoma Cells to Chemotherapeutic Cell Kill. Co-author DOI 10.3390/cancers13071679↗
  9. Alterations in driver genes are predictive of survival in patients with resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/cncr.33038↗
  10. Induction and characterization of pancreatic cancer in a transgenic pig model. Co-author DOI 10.1371/journal.pone.0239391↗
  11. Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adeno… Last author DOI 10.1002/cncr.31218↗
  12. Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: Challenges and Recommendations. Co-author DOI 10.1158/1078-0432.ccr-17-3099↗
  13. A phase 1/1B trial of ADI-PEG 20 plus nab-paclitaxel and gemcitabine in patients with advanced pancreatic adenocarcinoma. Co-author DOI 10.1002/cncr.30897↗
  14. Overall survival and clinical characteristics of BRCA mutation carriers with stage I/II pancreatic cancer. Co-author DOI 10.1038/bjc.2017.19↗
  15. Genomic instability in pancreatic adenocarcinoma: a new step towards precision medicine and novel therapeutic approaches. Co-author DOI 10.1586/17474124.2016.1153424↗
  16. Identification of germline genetic mutations in patients with pancreatic cancer. Co-author DOI 10.1002/cncr.29664↗
  17. Combined modality therapy in pancreatic adenocarcinoma: review and updates on a controversial issue. First author DOI 10.2174/1381612820666140826154724↗
  18. Modified GTX as Second-Line Chemotherapy in Advanced Pancreatic Cancer. Co-author PMID 24147159↗
  19. Prevalence of BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and pancreatic cancer. Co-author DOI 10.1002/cncr.26191↗
  20. Analysis of incidence and clinical outcomes in patients with thromboembolic events and invasive exocrine pancreatic cancer. Co-author DOI 10.1002/cncr.26600↗
  21. Neoadjuvant Therapy in Clinical Stage II Pancreatic Adenocarcinoma. Co-author PMID 23112885↗
  22. A 67-year-old woman with BRCA 1 mutation associated with pancreatic adenocarcinoma. Co-author DOI 10.1007/s12029-010-9197-1↗
  23. Targeting mutated K-ras in pancreatic adenocarcinoma using an adjuvant vaccine. Co-author DOI 10.1097/coc.0b013e3181e84b1f↗
  24. An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directions. First author DOI 10.1634/theoncologist.2011-0185↗

Trials 2

  1. A Registry for BRCA Mutation Carriers With Pancreatic Ductal Adenocarcinoma Principal investigator NCT01983410↗
  2. Gemcitabine Plus Radiation Therapy in Treating Patients With Pancreatic Cancer Study chair NCT00003426↗

Closest collaborators

The 25 strongest of 90 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Eileen Mary O'Reilly · 16 shared papers, 2011–2025 · strength 1.06
  2. Kenneth H. Yu · 11 shared papers, 2011–2025 · strength 0.98
  3. Marinela Capanu · 9 shared papers, 2011–2025 · strength 0.79
  4. Anna M. Varghese · 5 shared papers, 2018–2025 · strength 0.61
  5. Christine A. Iacobuzio–Donahue · 6 shared papers, 2016–2025 · strength 0.58
  6. Wungki Park · 4 shared papers, 2020–2025 · strength 0.55
  7. William R. Jarnagin · 4 shared papers, 2020–2025 · strength 0.54
  8. Zsofia Kinga Stadler · 7 shared papers, 2011–2025 · strength 0.46
  9. Ghassan K. Abou‐Alfa · 6 shared papers, 2011–2025 · strength 0.43
  10. Fiyinfolu O. Balogun · 2 shared papers, 2025 · strength 0.34
  11. Alice Chia-Chi Wei · 2 shared papers, 2025 · strength 0.34
  12. Maeve Aine Lowery · 7 shared papers, 2011–2018 · strength 0.33
  13. Erin E. Salo‐Mullen · 6 shared papers, 2011–2018 · strength 0.28
  14. Andrew S. Epstein · 5 shared papers, 2011–2022 · strength 0.27
  15. Olca Baştürk · 2 shared papers, 2020–2025 · strength 0.27
  16. Vinod P. Balachandran · 2 shared papers, 2020–2025 · strength 0.26
  17. T. Peter Kingham · 2 shared papers, 2020–2025 · strength 0.26
  18. Michael Ian D'Angelica · 2 shared papers, 2020–2025 · strength 0.26
  19. Jeffrey A. Drebin · 2 shared papers, 2020–2025 · strength 0.26
  20. Talia Golan · 3 shared papers, 2017–2022 · strength 0.23
  21. Mark Andrew Schattner · 1 shared paper, 2025 · strength 0.17
  22. Fergus Keane · 1 shared paper, 2025 · strength 0.17
  23. Fionnuala Crowley · 1 shared paper, 2025 · strength 0.17
  24. Kevin C. Soares · 1 shared paper, 2025 · strength 0.17
  25. Darren Cowzer · 1 shared paper, 2025 · strength 0.17

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.